Trust Co. of Vermont Sells 582 Shares of Novo Nordisk A/S (NYSE:NVO)

Trust Co. of Vermont lowered its position in Novo Nordisk A/S (NYSE:NVO) by 2.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 28,025 shares of the company’s stock after selling 582 shares during the period. Trust Co. of Vermont’s holdings in Novo Nordisk A/S were worth $3,337,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Armstrong Fleming & Moore Inc boosted its holdings in Novo Nordisk A/S by 7.1% in the 3rd quarter. Armstrong Fleming & Moore Inc now owns 7,532 shares of the company’s stock worth $897,000 after buying an additional 500 shares during the period. Good Life Advisors LLC boosted its holdings in Novo Nordisk A/S by 8.7% in the 3rd quarter. Good Life Advisors LLC now owns 28,655 shares of the company’s stock worth $3,412,000 after buying an additional 2,293 shares during the period. Naviter Wealth LLC boosted its holdings in Novo Nordisk A/S by 1.1% in the 3rd quarter. Naviter Wealth LLC now owns 62,589 shares of the company’s stock worth $7,452,000 after buying an additional 684 shares during the period. Mezzasalma Advisors LLC boosted its holdings in Novo Nordisk A/S by 4.7% in the 3rd quarter. Mezzasalma Advisors LLC now owns 24,007 shares of the company’s stock worth $2,859,000 after buying an additional 1,085 shares during the period. Finally, Bfsg LLC boosted its holdings in shares of Novo Nordisk A/S by 97.1% during the 3rd quarter. Bfsg LLC now owns 86,617 shares of the company’s stock valued at $10,313,000 after purchasing an additional 42,662 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 0.2 %

Shares of NYSE NVO opened at $118.22 on Friday. The firm’s 50-day moving average price is $128.79 and its 200-day moving average price is $131.72. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $530.52 billion, a price-to-earnings ratio of 40.77, a P/E/G ratio of 1.53 and a beta of 0.42. Novo Nordisk A/S has a 12-month low of $92.94 and a 12-month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. The firm had revenue of $9.82 billion during the quarter, compared to analysts’ expectations of $9.91 billion. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.01 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 16th were given a $0.5126 dividend. This represents a yield of 0.7%. The ex-dividend date was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 24.83%.

Analyst Ratings Changes

NVO has been the subject of several research reports. BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, October 10th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.